Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura N Puentes

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Molecular Imaging: PARP-1 and BeyondLaura N Puentes, Mehran Makvandi, Robert H Mach
Pharmacology & Therapeutics|August 15, 2021
PARkinson's: From cellular mechanisms to potential therapeuticsZsofia Lengyel-Zhand, Laura N Puentes, Robert H Mach
Molecular Neurobiology|March 31, 2021
Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's DiseaseLaura N Puentes, Zsofia Lengyel-Zhand, Sean W Reilly, et al.
ACS Omega|September 11, 2018
Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein InteractionsSean W Reilly, Laura N Puentes, Chia-Ju Hsieh, et al.
Journal of Medicinal Chemistry|June 2, 2018
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and CytotoxicitySean W Reilly, Laura N Puentes, Khadija Wilson, et al.
Frontiers in Aging Neuroscience|July 5, 2021
Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD SamplesLaura N Puentes, Zsofia Lengyel-Zhand, Ji Youn Lee, et al.
Bioorganic Chemistry|November 4, 2018
Synthesis and evaluation of an AZD2461 [<sup>18</sup>F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrantSean W Reilly, Laura N Puentes, Alexander Schmitz, et al.
Molecular Cancer Therapeutics|May 11, 2019
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsMehran Makvandi, Hwan Lee, Laura N Puentes, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Molecular Imaging: PARP-1 and BeyondLaura N Puentes, Mehran Makvandi, Robert H Mach
Pharmacology & Therapeutics|August 15, 2021
PARkinson's: From cellular mechanisms to potential therapeuticsZsofia Lengyel-Zhand, Laura N Puentes, Robert H Mach
Molecular Neurobiology|March 31, 2021
Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's DiseaseLaura N Puentes, Zsofia Lengyel-Zhand, Sean W Reilly, et al.
ACS Omega|September 11, 2018
Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein InteractionsSean W Reilly, Laura N Puentes, Chia-Ju Hsieh, et al.
Journal of Medicinal Chemistry|June 2, 2018
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and CytotoxicitySean W Reilly, Laura N Puentes, Khadija Wilson, et al.
Frontiers in Aging Neuroscience|July 5, 2021
Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD SamplesLaura N Puentes, Zsofia Lengyel-Zhand, Ji Youn Lee, et al.
Bioorganic Chemistry|November 4, 2018
Synthesis and evaluation of an AZD2461 [<sup>18</sup>F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrantSean W Reilly, Laura N Puentes, Alexander Schmitz, et al.
Molecular Cancer Therapeutics|May 11, 2019
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsMehran Makvandi, Hwan Lee, Laura N Puentes, et al.
Pageof 1